Asthma is a chronic airway inflammatory disorder that develops through a variety of mechanisms, each leading to different clinical manifestations and responsiveness to treatment. Although the majority of asthma cases can be controlled with standard treatments, a subset of asthmatic patients have ''severe'' or ''refractory'' asthma. 1 Recent work has shown that these cases are associated with the presence of T H 2/T H 17 CD4
1 T cells and that these cells drive more severe disease than classical T H 2 CD4
1 T cells. [2] [3] [4] Moreover, levels of IL-17A or IL-17A-producing CD4
1 cells in the lung, sputum, and blood of asthmatic patients correlate with disease severity. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, both genetic and environmental factors that contribute to T H 2-and T H 17-associated asthma development remain unclear.
GTPase of immunity-associated protein 5 (GIMAP5) is critical for lymphocyte survival, with Gimap5-deficient CD4
1 T cells demonstrating impaired survival and increased DNA damage on antigenic stimulation. [12] [13] [14] Complete loss-of-function (LOF) mutations in GIMAP5, both in rodents and in human subjects, result in lymphopenia, loss of immunologic tolerance, and subsequent development of autoimmunity. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In the context of Gimap5-deficient (Gimap5 sph/sph ) mice, this manifests as CD4
1
T cell-driven colitis. Importantly, polymorphisms in GIMAP5 have been associated with increased risk for type 1 diabetes and systemic lupus erythematosus, and a recent study revealed a single nucleotide polymorphism (SNP) in the promoter region of GIMAP5 to be associated with asthma. [22] [23] [24] [25] However, it remains unclear how polymorphisms in GIMAP5 predisposes subjects to these inflammatory diseases.
In the current study we show that Gimap5 deficiency drives the development of pathogenic CD4
1 T cells with an exaggerated T H 17 cell response and a more severe asthma phenotype.
METHODS

Study design
For the proposed experiments involving studies of immune responses in vivo, both male and female mice were used. All mice used were generated on a C57BL/6J background, and background purity was confirmed by using whole-genome SNP analysis. CD4
1 T cells from 3-to 4-week-old mice were used, unless otherwise noted, to minimize confounding by 1 T cells, with a normal frequency of naive T cells that exhibit a quiescent phenotype comparable with that of wild-type (WT) mice. Because we were interested in T-cell proliferation/survival in WT versus Gimap5-deficient cells, we expected to find strong differences in measurement (eg, normal vs absence of T-cell survival/proliferation). In cases in which the differences in the observed phenomena were clear and distinct, a group size of 6 mice was suitable to produce statistically significant (ie, P < .05) data. For these studies, we estimated that, with a sample size of 6, we have a 99% power to detect at least 25% reduction in the percentage of proliferating cells in stimulated Gimap5 sph/sph cells with a significant level (a) of .05 (2-tailed).
Mice and reagents
All experiments were performed according to US National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee of Cincinnati Children's Hospital. C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, Me). Deletion of Gimap5 in Gimap5 flox/flox Cd4 cre-ert2 mice was induced by administration of tamoxifen chow (40 mg/kg body weight; Teklad Diets; Harlan Laboratories, Indianapolis, Ind). Gimap5 sph/sph mice were generated, as previously described, 6 and bred in house in the vivarium of Cincinnati Children's Hospital. All mice were maintained under specific pathogen-free conditions.
All antibodies used for flow cytometry were purchased from eBioscience (San Diego, Calif) or BioLegend (San Diego, Calif), unless otherwise noted. Purified a-mouse CD3 (17A2) and a-mouse CD28 (37.51) antibodies (BioLegend) were used for mouse T-cell activation. A fixable viability stain was purchased from eBioscience. 7-Aminoactinomycin D was purchased from BD (Franklin Lakes, NJ). Phorbol 12-myristate 13-acetate (PMA), ionomycin, and Brefeldin A were obtained from Sigma (St Louis, Mo). aIFN-g (XMG1.2) and mIL-23 were obtained from eBioscience. TGF-b1, mIL-4, and hIL-2 were purchased from Miltenyi Biotech (Bergisch Gladbach, Germany). aIL-4, IL-6, and mIL-1b, mIL-12, and TGF-b3 were obtained from PeproTech (Rocky Hills, NJ).
Generation of Gimap5
flox/flox mice CRISPR/Cas9 was used to insert LoxP sites flanking the second exon of Gimap5 (see Fig E1, A, in this article's Online Repository at www.jacionline. org). Because the second exon contains the translation start site, deletion of this exon is expected to result in loss of Gimap5 protein (see Fig E2, A, in this article's Online Repository at www.jacionline.org). The accuracy of the insert was confirmed through sequencing (see Fig E1, B) . The presence of the LoxP sites was confirmed through PCR genotyping, as shown in Fig E1 
Flow cytometry and T-cell analyses
T-cell proliferation was quantified by incubating Mojo-purified (BioLegend) CD4
1 T cells in 5 mmol/L CellTrace Violet (CTV) in 0.2% FBS for 20 minutes. Cells were cultured in supplemented Iscove modified Dulbecco medium containing 10% FBS, 2% penicillin/ streptomycin, 1% L-glutamine, and 50 mmol/L b-Mercaptoethanol (BME). Cells were either left unstimulated or were stimulated with aCD3 (1 mg/mL)/aCD28 (2 mg/mL) in the presence of TGF-b1 (2 ng/mL). After 3 days of incubation, proliferation was evaluated by analyzing CTV dilution by using flow cytometry. Viability was determined by staining with a fixable viability dye. DNA damage was evaluated by means of phosphorylated histone H2AX (gH2AX) staining in conjunction with intracellular 7-aminoactinomycin D staining for cell-cycle analysis.
Lymphocytes from the spleens, mesenteric lymph nodes (mLNs), mediastinal lymph nodes, and lungs were isolated and stained with fluorochrome-conjugated antibodies for mouse CD3, CD4, CD19, CD44, gH2AX, T-bet, retinoic acid-related orphan receptor gt (RORgt), Gata-3, and forkhead box P3 (Foxp3) to evaluate lymphocyte populations ex vivo. Lymphocytes from the spleens, mLNs, mediastinal lymph nodes, and lungs were restimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL) in the presence of Brefeldin A for 6 hours before staining with fluorochrome-conjugated antibodies for mouse IFN-g, IL-13, and IL-17A to evaluate CD4 1 T-cell cytokine production capacity. Except where noted in in vitro experiments, all data were generated from live cells, as determined by using fixable viability dye staining.
In vitro CD4 1 T-cell polarization
Mojo-purified (BioLegend) naive CD4 1 T cells were isolated from spleens and peripheral lymph nodes (cervical, brachial, axillary, and inguinal) of 3-to 4-week-old mice and labeled with 5 mmol/L CTV in 0.2% FBS for 20 minutes to test CD4 1 T-cell polarization. Cells were cultured in supplemented RPMI media containing 10% FBS, 2% penicillin/streptomycin, and 50 mmol/L BME. Cells were stimulated with aCD3 (1 mg/mL)/aCD28 (2 mg/mL) alone or in the presence of polarizing cytokines (see Table E1 in this article's Online Repository at www. jacionline.org). 
Mouse asthma model
Airway hyperresponsiveness
Mice were anesthetized with ketamine, xylazine, and acepromazine (100, 20, and 10 mg/mL, respectively, mixed at a ratio of 4:1:1). Invasive measurements of airway responsiveness were made with the flexiVent apparatus (SCIREQ, Montreal, Quebec, Canada). Mouse tracheas were cannulated with a 19-gauge blunt needle; mice were ventilated at 150 breaths/min and 3.0 cm of water positive end-expiratory pressure. Two total lung capacity perturbations were then performed for airway recruitment before baseline measurement, and subsequent methacholine challenges were performed. Dynamic resistance was assessed after exposure to increasing concentrations of aerosolized methacholine (0, 12.5, 25, 50, and 100 mg/mL). The average of the 3 highest dynamic resistance values with a coefficient of determination of 0.9 or greater (as determined by flexiVent software) was used to determine the dose-response curve.
Bronchoalveolar lavage fluid cell collection and analysis
Bronchoalveolar lavage (BAL) was performed by means of tracheal cannulation. Lungs were lavaged with 1 mL of PBS. After counting the number of cells with a hemocytometer, cells were spun onto slides and stained with the HEMA3 stain set (Fisher Scientific, Waltham, Mass). After deidentifying samples, approximately 200 cells were counted, and numbers of macrophages, neutrophils, and eosinophils were calculated.
Isolation and characterization of lung-infiltrating cells
After lavage, lungs were removed, and the upper right lobe was minced and digested in 2 mL of RPMI plus 0.5 mg/mL Liberase DL (Roche Diagnostics, Mannheim, Germany) and 0.5 mg/mL DNAse I (Sigma) at 378C for 30 minutes. Cells were then passed over a 70-mm cell strainer. Cells were washed with PBS and counted. Approximately 1 3 10 6 cells were stimulated with 50 ng/mL PMA plus 500 ng/mL ionomycin for 6 hours. After 2 hours, Brefeldin A was added. CD4
1 T cells were stained with a viability dye (eBioscience Live/Dead stain) and antibodies for CD3, CD4, CD44, and gd T-cell receptor; intracellular staining for IL-13, IL-17A, and IFN-g was performed after fixation and permeabilization, according to the manufacturer's instructions (eBioscience). Foxp3 staining was performed on separate cells that had not been restimulated ex vivo.
Histology
Lung tissue was collected and immediately fixed in 10% buffered formalin solution, followed by routine paraffin embedding. Periodic acid-Schiff and hematoxylin and eosin staining was performed on 4-mm sections from the paraffin-embedded tissue blocks for conventional light microscopy.
Analysis of human T cells
For all studies concerning human cells, informed consent was obtained, and studies were approved by the Cincinnati Children's Hospital Medical Center Institutional Review Board. PBMCs were isolated from whole blood of a GIMAP5-deficient patient, a healthy parent (heterozygous for GIMAP5 rs72650695), and unrelated healthy control subjects by using Ficoll-Paque Plus density gradient centrifugation. Isolated PBMCs were cultured in RPMI, 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mmol/L L-glutamine, and 10 mmol/L HEPES and were stimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL) in the presence of Brefeldin A and analyzed for IFN-g, IL-17A, and IL-13 production by using flow cytometry.
Immunoblotting
Protein lysates from Mojo-isolated (BioLegend) CD4
1 T cells were prepared according to standard methods from resting cells. Lysates were separated by using 10% Bis-Tris Gels, transferred onto nitrocellulose, and immunoblotted with primary antibodies to Gimap5 (MAC421) 12 and b-actin (CST).
Analysis and graphics software
Flow cytometric data were analyzed by using FlowJo software (TreeStar, Ashland, Ore). All data were analyzed for statistical significance by using GraphPad Prism 4 software (GraphPad Software, San Diego, Calif). The graphical abstract was created with BioRender. Figure components were generated in FlowJo or GraphPad Prism software (GraphPad Software, La Jolla, Calif) and assembled in Adobe Illustrator (Adobe, San Jose, Calif).
Statistical analysis
Data are expressed as means 6 SDs, except for where otherwise noted. For studies comparing T cells from C57BL/6J, Gimap5 sph/sph , and/or Gimap5 fl/fl Cd4 cre-ert2 mice, the Student 2-tailed test or ANOVA followed by the Sidak multiple comparisons test for 3 or more groups were used. Data were considered statistically significant if P values were less than .5.
RESULTS
GIMAP5 LOF mutations in mice and human subjects promote development of T H 17/T H 2 CD4
1
T cells in vivo
Given that polymorphisms in GIMAP5 have been associated with increased risk for type 1 diabetes, systemic lupus erythematosus, and asthma [22] [23] [24] [25] and our previous studies revealed the development of CD4-dependent colitis in Gimap5-deficient mice, 14, 15 we first investigated whether baseline differences in CD4
1 T-cell polarization exist in vivo. To assess this, we examined the CD4
1 T-cell compartment in the spleens and mLNs of 8-week-old WT and Gimap5 sph/sph mice. As previously described, CD4
1 T cells were reduced in the spleens of Gimap5 sph/sph mice (Fig 1, A) . Importantly, however, an increased proportion of the remaining Gimap5 sph/sph CD4 1 T cells were polarized to T H 2 cells (Gata-3 
CD4
1 ) compared with WT mice (Fig 1, B) . Furthermore, Gimap5 sph/sph splenic CD4
1 T cells more frequently produced IFN-g, IL-17A, and/or IL-13 compared with WT CD4
1 T cells (Fig 1, C-E). Notably, Gimap5 sph/sph mice had expanded frequencies of CD4 1 T cells that produced both IFN-g 1 IL-17A 1 or IL-13 1 IL-17A 1 (Fig 1, F and G). These cells have been associated with pathology in patients with several autoimmune diseases and asthma, respectively. 2, 3, [26] [27] [28] [29] [30] [31] Interestingly, the mLNs of Gimap5 sph/sph mice contained similar numbers of total CD4
1 T cells compared with WT littermates, but a greater frequency expressed T-bet, Gata-3, or RORgt compared with WT littermates (Fig 1, H and I ). Similar to the spleen, an increased proportion of CD4 1 T cells in the mLNs were IFN-g 
IL-17A
1 double producers (Fig 1, J-N) . Together, these observations suggest that loss of Gimap5 is associated with an increased polarization of effector CD4
1 T cells, including development of pathogenic CD4
1 T cells that can drive immunopathology.
Previously, we described a patient with an LOF mutation in GIMAP5 (rs72650695; a missense variant leading to a Leu204/ Pro amino acid change and a complete loss of protein expression), 14 resulting in an immunodeficiency with features of autoimmunity. Functional characterization of CD4 1 T cells from this patient revealed strikingly similar molecular defects to Gimap5-deficient mouse CD4
1 T cells. 14 Therefore we asked whether the patient has similarly skewed the CD4 1 T-cell compartment. Strikingly, a greater proportion of the patient's circulating CD4
1 T cells expressed IL-17A, IL-13, or IFN-g compared with the patient's heterozygous mother or unrelated control subjects on stimulation with PMA and ionomycin (Fig  1, O-Q) . Furthermore, an increased frequency of CD4 1 T cells coexpressed IL-17A 1 IL-13 1 or IL-17A 1 IFN-g 1 (Fig 1, R and S). Although we were only able to study a single patient with GI-MAP5 deficiency, the increased development of pathogenic peripheral T H 2 and T H 17 cells in the GIMAP5-defcient patient is consistent with our mouse data.
Notably, this predilection toward T H 17 polarization can be observed in in vitro culture systems. In previous studies we observed that bulk Gimap5 sph/sph CD4 1 T cells have an impaired proliferation and survival on stimulation with aCD3/aCD28 (Fig 2, A and B) , and only a small subset is able to survive and proliferate.
12,14 A more in-depth evaluation of surviving cells demonstrates expression of high levels of RORgt, indicating either a selective survival of T H 17-polarized cells or a predisposition of surviving cells to adopt a T H 17 (Fig 2, C) . Together, these data suggest that GIMAP5 deficiency in both human subjects and mice causes CD4
1 T cells to preferentially adopt a T H 17 phenotype both in vitro and in vivo. ), his heterozygous parent, and unrelated control subjects (n 5 2, 2, and 7, respectively) are shown. *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Not significant.
Selective survival of Gimap5-deficient CD4
1 T cells under different polarizing conditions Both Gimap5-deficient rodents and human subjects have lymphopenia, [12] [13] [14] [15] [16] [17] [18] [19] and thus it is unclear whether the increased prevalence of T H 17 cells in vivo is due to a skewing of polarization or selective survival of T H 17 cells. Similarly, expression of RORgt by almost all surviving Gimap5-deficient CD4
1 T cells could be due to the survival of cells or merely the consequence of surviving cells polarizing to T H 17 cells in vitro.
Naive CD4 1 T cells were isolated from 3-to 4-week-old WT and Gimap5 sph/sph mice and stimulated with aCD3/aCD28 in T H 0-, T H 1-, T H 2-, T H 17-, or induced regulatory T (iTreg)-polarizing conditions for 3 days (as detailed in Table E1 ) before evaluating survival and proliferation to differentiate between these possibilities. As with total CD4 1 T cells, naive Gimap5 sph/sph CD4 1 T cells exhibited reduced survival and proliferation when stimulated with aCD3/aCD28 (T H 0 conditions) compared with WT CD4
1 T cells (Fig 3, A and B) . A similar defect was observed in T H 1-polarizing conditions. This defect was primarily characterized by Gimap5 sph/sph cells unable to complete the cell cycle, although a considerable proportion of cells died after cycling. Stimulation in T H 2-polarizing conditions resulted in a more bifurcated response, with a subset of cells exhibiting strong proliferation, whereas a significant number of cells died without completing the cell cycle. Strikingly, compared with WT mice, naive Gimap5 sph/sph CD4 1 T-cell survival and proliferation were completely normal in T H 17-and iTreg-polarizing conditions. Notably, both T H 17-and iTreg-polarizing conditions include TGF-b1; therefore we asked whether TGF-b signaling promoted Gimap5 sph/sph CD4 1 T-cell survival and proliferation during T H 17 polarization. Previously, Lee et al 32 identified different T H 17-polarizing conditions by using combinations of TGF-b1, TGF-b3, IL-6, IL-23, and IL-1b (see Table E1 ).
To test the contribution of TGF-b and the T H 17 transcriptional program to Gimap5 sph/sph CD4 1 T-cell survival, we stimulated naive CD4 1 T cells in T H 17-polarizing conditions containing TGF-b1, TGF-b3, or anti-TGF-b1. Although Gimap5 sph/sph
CD4
1 T-cell survival and proliferation were improved in T H 17-polarizing conditions lacking TGF-b signaling over T H 0 conditions, survival was significantly reduced compared with T H 17-polarizing conditions containing TGF-b1 or TGF-b3 (Fig  3, C) . These data suggest that TGF-b is a critical mediator of Gimap5-deficient CD4
1 T-cell survival, ultimately promoting the development of pathogenic T H 17 cells.
Activation of Gimap5
sph/sph CD4 1 T cells results in increased DNA damage that is mitigated by TGF-b1
We have previously reported that poor survival of Gimap5 sph/ sph CD4 1 T cells on aCD3/aCD28 stimulation correlated with exacerbated DNA damage.
14 Therefore we asked whether the reduced survival in different polarizing conditions was associated with exacerbated DNA damage. Specifically, we assessed the level of gH2AX in live dividing CD4
1 T cells as a marker for double-stranded DNA breaks. Interestingly, high levels of gH2AX were observed, even in WT CD4
1 T cells, when stimulated under T H 0, T H 1, or T H 2 conditions, whereas T H 17 and iTreg conditions were associated with comparatively modest DNA damage after 3 days of polarizing conditions (Fig 3, D) . Importantly, Gimap5 sph/sph CD4 1 T cells consistently showed increased DNA damage in T H 0, T H 1, or T H 2 conditions compared with WT conditions (Fig 3, D) , although gH2AX levels in both WT and Gimap5 sph/sph CD4 1 T cells were reduced in polarizing conditions containing either TGF-b1 or TGF-b3. Notably, increased DNA damage was also observed in Gimap5 sph/sph T H 1 (T-bet 
CD4
1 T cells are unable to control the DNA damage that occurs in T H 0-, T H 1-, and T H 2-polarizing conditions.
Given the preferential survival of Gimap5-deficient CD4 1 T cells stimulated in TGF-b-containing T H 17-and iTregpolarizing conditions, we next asked whether TGF-b1 signaling was sufficient to rescue CD4 1 T cells cultured in polarizing conditions associated with poor survival. Strikingly, proliferation and survival of Gimap5 sph/sph CD4 1 T cells were almost completely rescued with the addition of TGF-b1 in cells with these polarizing conditions (Fig 4, A and B) .
Notably, TGF-b is cleaved to its active form in the lung (and other tissues) after tissue injury, [33] [34] [35] [36] resulting in a TGF-b-rich environment. Because naive T cells are first activated in lymph (Fig 2, C) , whereas bar graphs (Fig 2, B) represent mean values 6 SDs (n 5 4). All experiments were performed at least 3 times. Statistical significance is determined by using the Student 2-tailed test. ****P < .0001.
nodes before migrating to the affected tissue, we asked whether exposure to TGF-b1 during the cycling phase, when DNA damage is most pronounced, was sufficient to promote survival of Gimap5 sph/sph CD4 1 T cells. Indeed, the addition of TGF-b1 after 1 or 2 days of stimulation/polarization robustly improved Gimap5 sph/sph CD4 1 T-cell survival, proliferation, and control of DNA damage in T H 0-, T H 1-, and T H 2-polarizing conditions, although it was insufficient to completely abrogate the effects of Gimap5 deficiency (Fig 4, C-H ). These data demonstrate that, independent of T H 17 or iTreg polarization, TGF-b1 is sufficient to rescue the survival of Gimap5 sph/sph CD4 1 T cells. Moreover, TGF-b1 signaling is not required at the time of initial aCD3/ aCD28 stimulation. Thus these studies identify TGF-b as an important mediator during CD4 1 T-cell differentiation, limiting DNA damage and improving survival and proliferation of activated Gimap5 sph/sph CD4 1 T cells and promoting the selective development of pathogenic T H 17 cells.
Gimap5 deficiency exacerbates allergic airway pathology
A recent study identifies GIMAP5 as a modifier gene in asthmatic patients. 25 Specifically, a 59 SNP (rs6965571) in the promoter region of GIMAP5 is associated with an approximately 3-fold increased risk of asthma in a prospective Swedish birth cohort, 25 although the mechanisms responsible for increased asthma risk are unclear. Given our findings that both GIMAP5-deficient mice and human subjects display a high frequency of T H 2 and T H 2/T H 17 pathogenic CD4 1 T cells in vivo and that T H 2/T H 17 allergic responses exacerbate the asthma phenotype, we assessed the role of Gimap5 in allergic airway disease. Based on the changes in T-cell polarization described above, we predicted that loss of Gimap5 would increase sensitivity to allergic airway disease, and therefore we used a mild model of experimentally induced allergic airway disease in C57BL/6J mice. 37, 38 Specifically, we sensitized Gimap5 sph/sph and control C57BL/6 WT mice with 9 intratracheal injections of 25 mg of HDM during a 3-week period, as previously described, 39 after which immune pathology was assessed. One day after the last exposure, mice were evaluated for airway hyperresponsiveness (AHR) and BAL inflammatory profile. Strikingly, HDM-sensitized Gimap5 sph/sph mice exhibited significantly greater AHR compared with HDM-sensitized WT mice and saline-treated mice (Fig 5, A) . The observed increase in AHR corresponded with a significantly increased infiltration of eosinophils and macrophages in the BAL fluid in HDM-sensitized Gimap5 sph/sph mice (Fig 5, B-D) . . All experiments were performed at least 3 times. Statistical significance is determined by means of ANOVA, followed by using the Sidak multiple comparisons test. *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Not significant.
Total lung infiltrating cells from the upper right lobe for each mouse were quantified, restimulated with PMA and ionomycin, and evaluated for cytokine production to determine whether exacerbated AHR and eosinophil/macrophage infiltration correlated with increased development of pathogenic CD4 1 T cells. Lungs from HDM-sensitized Gimap5 sph/sph mice had significantly more inflammatory infiltrate (Fig 5, E) and, importantly, exhibited a 4-fold increase in infiltrating CD4
1 T cells compared with WT mice (Fig 5, F) . The latter involved a marked increase in numbers of CD4 1 T cells producing IL-13 or IL-17 (Fig 5, G and H) and importantly also included a significant increase in numbers of pathogenic IL-13 (Fig 5, I ), which have been associated with severe immune pathology/disease. Similarly, lung-draining mediastinal lymph nodes of Gimap5 sph/sph mice displayed an increase in numbers of IL-13
, and IL-13
in this article's Online Repository at www.jacionline.org). Furthermore, HDM sensitization resulted in distortion of normal lung architecture, increased airway mucus production, marked edema, and lymphocytic infiltration in the interstitial space representative of perivascular inflammation (Fig 5, K and L) . Together, these data show that LOF mutations in Gimap5 exacerbate the asthma phenotype, which is associated with a significant expansion of pathogenic T H 2/T H 17 cells.
Polarization defects in Gimap5-deficient CD4
1
T cells are cell intrinsic
In addition to CD4 1 T cells, Gimap5 is expressed in innate lymphoid cells (ILCs), and our previous studies indicate that natural killer cell development/survival is markedly affected in (Fig 4, A) or T H 2-polarizing (Fig 4, B) conditions with or without 2 ng/mL TGF-b1. Blue histograms represent dead cells; red histograms show live cells. C-H, Survival, proliferation, and gH2AX expression of naive CD4 1 T cells stimulated in T H 0-polarizing (Fig 4, C and D) , T H 1-polarizing (Fig 4, E and F) , or T H 2-polarizing (Fig 4, G and H) conditions. At 1 or 2 days after initial stimulation, 2 ng/mL TGF-b1 was added to the indicated culture. Data represent mean values 6 SDs (n 5 4). Statistical significance is determined by means of ANOVA, followed by the Sidak multiple comparisons test. *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Not significant.
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FIG 5.
Gimap5 sph/sph mice exhibit increased AHR, CD4 1 T-cell polarization, and airway pathology on HDM sensitization. C57BL/6 WT (black bars) and Gimap5 sph/sph (red bars) mice were administered 25 mg of HDM 9 times intratracheally over 3 weeks. A, AHR in response to methacholine challenge 1 day after the last HDM challenge (saline, n 5 3; HDM, n 5 5-6). B-D, Numbers of macrophages (MFs), neutrophils, and eosinophils in BAL fluid (saline, n 5 3; HDM, n 5 4-7). E and F, Numbers of total lung-infiltrating cells (Fig 5, E) and CD4 1 T cells (in 2 lobes; Fig 5, F) . G-J, Percentage of lung-infiltrating CD4 1 CD3 1 T cells expressing IL-13, IL-17A, IL-13 and IL-17A, or IFN-g on restimulation with PMA/ionomycin for 6 hours (saline, n 5 3; HDM, n 5 6-7). K and L, Representative hematoxylin and eosin-stained (Fig 5, K) and periodic acid-Schiff-stained (Fig 5, L) images of lung tissue from WT and Gimap5 sph/sph mice given saline or HDM. Data represent mean values 6 SDs. Statistical significance is determined by means of ANOVA, followed by the Sidak multiple comparisons test. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
Gimap5-deficient mice. 12, 19 Given the critical role for type 2 ILCs and type 3 ILCs in CD4
1 T-cell differentiation and asthma, [40] [41] [42] [43] [44] [45] we next asked whether the observed CD4 1 T-cell defects were cell intrinsic or whether other cell types might contribute to the impaired polarization of CD4 1 T cells. To do so, we generated the Gimap5 fl/fl mouse by using CRISPR/Cas9 on a C57BL/6 background. Loxp sites were placed on flanking exon 2 of Gimap5 (see Fig E1) , and subsequent Gimap5 fl/fl mice were crossed to Cd4 cre-ert2 mice, allowing the tamoxifen-inducible deletion of Gimap5 in CD4
1 T cells (conditional knockout [cKO] ). Effective ablation of Gimap5 expression in CD4
1 T cells was achieved with the administration of tamoxifen in chow (Fig 6, A) .
Similar to CD4 1 T cells isolated from the Gimap5 sph/sph mouse, Gimap5 fl/fl Cd4 cre-ert2 naive CD4 1 T cells demonstrated impaired survival and proliferation in T H 0-, T H 1-, and T H 2-polarizing conditions compared with that seen in WT control mice. Furthermore, no significant difference in survival and proliferation between WT and cKO CD4
1 T cells was observed in T H 17-polarizing conditions (Fig 6, B and C) . Together, these results correlated with DNA damage observed in cycling CD4
1 T cells with cKO CD4
1 T cells displaying increased gH2AX levels compared with WT CD4
1 T cells stimulated in T H 0-, T H 1-, T H 2-, and iTreg-polarizing conditions. Similar to Gimap5 sph/sph CD4 1 T cells, no difference in survival/proliferation was observed in T H 17-polarizing conditions. These data confirm that the impaired survival and increased DNA damage in stimulated Gimap5-deficient CD4 1 T cells are cell intrinsic.
Loss of Gimap5 in CD4
1 T cells is sufficient to drive exacerbated AHR and pathology
Because pathogenic CD4
1 T cells are one of the primary drivers of HDM-induced lung pathology, we investigated whether Gimap5 deficiency in CD4 1 T cells alone was sufficient to drive more severe disease in the HDM model of allergic asthma. To do so, 1 week after starting the tamoxifen chow, allergic airway disease was induced in WT and Gimap5 fl/fl Cd4 cre-ert2 mice as above. Comparable with Gimap5 sph/sph mice, conditional deletion of Gimap5 in CD4 1 T cells was sufficient to drive increased AHR in HDMsensitized mice (Fig 7, A) . Although exacerbated AHR was not specifically associated with changes in the numbers of macrophages and neutrophils in BAL fluid, the number of infiltrating eosinophils trended upward in HDM-sensitized Gimap5 fl/fl Cd4 cre-ert2 mice compared with WT mice (Fig 7, B-D) . Interestingly, although the numbers of lung-infiltrating CD4
1 T cells in HDM-sensitized Gimap5 fl/fl Cd4 cre-ert2 mice were similar or even slightly reduced compared with those in WT mice (Fig 7, E and F) , a greater proportion expressed an activated phenotype (CD44 hi ; Fig 7, G) . Furthermore, they exhibited an increased frequency of CD4 1 T cells producing IL-13, IL-17A, or both IL-17A and IL-13 together (Fig 7, H-J) , whereas the frequency of IFN-g 1
CD4
1 T cells was reduced compared with that in WT mice (Fig 7, K) . Notably, similar levels of CD4
1 Treg cells were observed in the lungs of WT and Gimap5 fl/fl Cd4 cre-ert2 mice, indicating that the development of iTreg cells and/or recruitment is not affected in this model (see Fig E5, A, in this article's Online Repository at www. jacionline.org). B cells were likewise unaffected (Fig E5, B) . Similar to the Gimap5 sph/sph mice, HDM sensitization resulted in edema with perivascular inflammation and increased mucus production in the lungs of cKO mice (Fig 7, L and M) . These data reveal that the conditional loss of Gimap5 in CD4
1 T cells is sufficient to drive the development of pathogenic CD4 1 T cells and exacerbate allergy-like lung disease upon HDM sensitization.
Because we have previously shown that Gimap5-deficient Treg cells have impaired suppressive capacity, we next asked whether defective Treg cells were responsible for the development of more severe airway disease. Interestingly, selective ablation of Gimap5 in Treg cells was insufficient to drive exacerbated airway disease and development of pathogenic CD4
1 T cells, indicating that loss of Gimap5 intrinsically promotes the polarization of pathogenic CD4 1 T cells (see Fig E2) .
DISCUSSION
Here we describe a key role for Gimap5 in the prevention of pathogenic CD4
1 T-cell development and show that loss of Gimap5 is associated with an increased risk for allergic lung disease. Specifically, HDM sensitization of Gimap5-deficient mice results in severe AHR, eosinophil recruitment to the lung, and an exacerbated T H 2/T H 17 response. The increased airway inflammation was also observed in conditional loss of Gimap5 in CD4
1 T cells, demonstrating that these cells are the primary driver of HDMinduced lung pathology. Moreover, even in the absence of HDM sensitization, Gimap5 sph/sph CD4 1 T cells progressively adopt an inflammatory phenotype, with T H 17 cells being particularly prominent. Importantly, the abnormal CD4
1 T-cell polarization profile is also observed in a GIMAP5-deficient patient who exhibited increased development of pathogenic CD4
1 T cells in the periphery. Thus despite the observed lymphopenia in both Gimap5-deficient mice and human subjects, the selective survival of pathogenic T H 17 cells might be a key driver of immune pathology in the setting of allergic airway disease.
Our current findings that loss of GIMAP5 leads to pathogenic CD4 1 T-cell development might help us understand how the GIMAP5 polymorphism rs6965571 in the promoter region of GIMAP5 predisposes to asthma development. 25 The rs6965571 SNP is adjacent to a Foxo1 binding site (upstream) and a nuclear factor of activated T cells 1 (NFATc1) binding motif (downstream) and could affect the binding of these transcription factors (TFs) to regulate GIMAP5 expression. Interestingly, our previous studies identified impaired Foxo1 expression 15 and NFATc1 activity on stimulation of Gimap5-deficient CD4 1 T cells. 14 Thus a potential feed-forward loop exists in which Gimap5 expression is required for the expression and activity of TFs that in turn regulate the transcriptional expression of GIMAP5. Thus the SNP can cause a progressive loss of GIMAP5 expression after T-cell activation, leading to increased development of T H 2/T H 17 cells that promote immune pathology in the lung. Previously, the presence of T H 2/T H 17 cells has been associated with more severe disease, and adoptive transfer experiments in mice have demonstrated that these cells are more pathogenic than classic T H 2 cells. [2] [3] [4] Furthermore, increased levels of IL-17A, either from these double producers or classic T H 17 cells, have been linked to more severe disease and steroid resistance in human patients. [5] [6] [7] [8] [9] [10] [11] These increased IL-17A levels can drive increased pathology directly through recruitment of neutrophils, or indirectly by modulating T H 2 pathogenicity by enhancing IL-13/signal transducer and activator of transcription 6 signaling, as shown by Hall et al. 46 Thus a critical future question to address is to identify the effect of the rs6965571 polymorphism on GIMAP5 expression on T-cell activation and to establish whether patients with this SNP have an increased number of pathogenic (T H 17) CD4
1 T cells. . Statistical significance is determined by means of ANOVA, followed by the Sidak multiple comparisons test. *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Not significant.
Although DNA damage occurs normally upon mitogenic stimulation in CD4
1 T cells, a key finding is that the exacerbated DNA damage in cycling Gimap5-deficient CD4
1 T cells and reduced T-cell survival is independent of Fas-signaling or intrinsic apoptotic cascades.
14 Importantly, our previous studies identified a key role for Gimap5 in regulating glycogen synthase kinase 3 (GSK3) activity and subsequent control of the DNA damage response during CD4 1 T-cell proliferation. 14 Here we show that DNA damage was particularly associated with T H 1-and T H 2-polarizing conditions. Interestingly, the presence of TGF-b could limit the extent of DNA damage, even in T H 1-and T H 2-polarizing conditions. Previous studies have shown Cd4 cre-ert2 (red data points) mice were administered 50 mg of HDM 9 times intratracheally over 3 weeks. A, AHR in response to methacholine challenge 1 day after the last HDM challenge (saline, n 5 4-5; HDM, n 5 7-8). B-D, Number of macrophages (MFs), neutrophils, and eosinophils in BAL fluid (saline, n 5 4-5; HDM, n 5 8). E and F, Number of total lung-infiltrating cells (in 2 lobes; Fig 7, E) and frequency of CD4 1 CD3 1 T cells therein (Fig 7, F) . G, PMA/ionomycin for 6 hours (saline, n 5 4-5; HDM, n 5 8). L and M, Representative hematoxylin and eosin (Fig 7, L) and periodic acid-Schiff (Fig 7, M) images of lung tissue from WT and Gimap5 fl/fl Cd4 cre-ert2 mice given saline or HDM. Data represent mean values 6 SDs. Statistical significance is determined by means of ANOVA, followed by the Sidak multiple comparisons test. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
that TGF-b signaling can promote DNA damage repair and cell viability by inducing activation of ataxia-telangiectasia mutated (ATM), 47, 48 suggesting that TGF-b signaling can overcome the exacerbated DNA damage observed in activated Gimap5-deficient CD4 1 T cells. Moreover, we show that initiation of TGF-b signaling even 2 days after initial T-cell receptor stimulation is sufficient to reduce cell death and DNA damage in vitro in Gimap5-deficient CD4 1 T cells. In vivo this would translate to improved survival of newly activated CD4
1 T cells encountering TGF-b in the lung or other TGF-b-rich tissues. We posit that the ability of TGF-b to overcome the survival defects associated with Gimap5 deficiency could affect the CD4 1 T-cell compartment by promoting the selective survival of T H 17 cells and other pathogenic CD4
1 T cells infiltrating the TGF-b-rich asthmatic lung, where they drive further immune pathology.
Somewhat paradoxically, Gimap5-deficient mice do not induce iTreg cells in vivo, and retained Treg cells have reduced suppressive capacity. 14, 15 It remains unclear why TGF-b rescues T H 17 CD4
1 T-cell development but not iTreg polarization and function, although our previous data suggest that the uncontrolled activity of GSK3b in the absence of Gimap5 might be critical to this process. Several independent studies demonstrate that GSK3b activity promotes T H 17 polarization while impairing iTreg cell activity, providing one possible mechanism by which T H 17 polarization is favored in the absence of Gimap5. [49] [50] [51] [52] [53] [54] [55] Furthermore, Foxo family members, which are poorly expressed in Gimap5-deficient CD4
1 T cells, 15 are key TFs in Treg cell development and function. 56, 57 Impaired expression of these TFs is predicted to be a critical factor in the inability of Gimap5 sph/sph mice to develop iTreg cells. This dysbalance between pathogenic CD4 1 T cells and functional Treg cells is one of the primary driving factors behind the immune pathologies associated with Gimap5 deficiency. Unfortunately, the inability of TGF-b to rescue iTreg cell function, its promotion of the development of pathogenic T H 17 CD4
1 T cells, and its critical role in the resolution of inflammation make it an impractical target in clinical applications. However, therapeutic targeting of other links in the GIMAP5 pathway, such as GSK3b, might offer more promise in clinical options for patients with GIMAP5-associated asthma.
We thank G. Butcher for graciously providing the MAC421 aGimap5 antibody.
Key messages
d GIMAP5 LOF mutations in mice and human subjects result in increased T H 2/T H 17 polarization in vivo.
d Gimap5-deficient CD4 1 T cells exhibit increased DNA damage and reduced survival on activation that can be overcome by TGF-b. Foxp3 cre (red data points) mice were administered 50 mg of HDM 9 times intratracheally over 3 weeks. A, Expression of Gimap5 in CD4 1 CD25 hi T cells isolated from WT and Gimap5 fl/fl Foxp3 cre mice. B, AHR in response to methacholine challenge 1 day after the last HDM challenge. C-E, Number of macrophages (MFs), neutrophils, and eosinophils in BAL fluid. F and G, Number of total lung-infiltrating cells (Fig E2, F) and CD4
1
CD3
1 T cells (Fig E2, G) (Fig E2, H) and numbers of Foxp3 1 Treg cells (Fig E2, I ). J-M, Percentage of lung-infiltrating CD4 1 CD3 1 T cells expressing IL-13, IL-17A, IL-13 and IL-17A, or IFN-g on restimulation with PMA/ionomycin for 6 hours. Data represent mean values 6 SDs (saline, n 5 2-3; HDM, n 5 6). Statistical significance is determined by means of ANOVA, followed by the Sidak multiple comparisons test. *P < .05. and IFN-g after restimulation with PMA/ionomycin. Black bars describe WT mice; red bars describe Gimap5 sph/sph mice. Data represent mean values 6 SDs (saline, n 5 3; HDM, n 5 6-7). Statistical significance is determined by means of ANOVA, followed by the Sidak multiple comparisons test. *P < .05, ***P < .001, and ****P < .0001.
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